Printer Friendly

CHEMTRAK INCORPORATED FILES INITIAL PUBLIC OFFERING

 CHEMTRAK INCORPORATED FILES INITIAL PUBLIC OFFERING
 SUNNYVALE, Calif., Feb. 5 /PRNewswire/ -- ChemTrak Incorporated,


manufacturer of the AccuMeter(R) Total Cholesterol Test, has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of 2,000,000 shares of common stock to be offered at an estimated price of $11 to $13 per share through an underwriting group managed by Dean Witter Reynolds Inc., Volpe, Welty & Company and Needham & Company, Inc.
 Net proceeds of the proposed offering will be used for working capital, manufacturing scale-up, research and development and other general corporate purposes.
 Founded in 1985, ChemTrak develops, manufactures and markets quantitative, easy-to-use, disposable diagnostic tests for worldwide point-of-care markets, including the consumer retail and physician office markets.
 A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
 A prospectus regarding the proposed initial public offering may be obtained from Dean Witter Reynolds Inc., Volpe, Welty & Company, or Needham & Company Inc.
 -0- 2/5/92
 /CONTACT: Terry Duryea, vice president-finance of ChemTrak, 408-773-8156/ CO: ChemTrak Incorporated ST: California IN: MTC SU: OFR SM -- NY009 -- 7022 02/05/92 08:52 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 5, 1992
Words:273
Previous Article:TIME WARNER ANNOUNCES MERGER AGREEMENT WITH AMERICAN TELEVISION AND COMMUNICATIONS
Next Article:RUBIDELL RECREATION CONCLUDES THREE YEAR BUSINESS PLAN
Topics:


Related Articles
UNDERWRITERS ANNOUNCE INITIAL PUBLIC OFFERING OF CHEMTRAK AT $13 PER SHARE
SYNAPTIC PHARMACEUTICAL FILES FOR INITIAL PUBLIC OFFERING OF COMMON STOCK; NAME CHANGED FROM NEUROGENETIC CORPORATION
CHEMTRAK REPORTS 1995 RESULTS: FOURTH QUARTER REVENUES OF $3.8 MIL.
CHEMTRAK GAINS RETURN OF MARKETING RIGHTS FOR HOME CHOLESTEROL TEST
CHEMTRAK FILES FOR FDA CLEARANCE OF H. PYLORI TEST
CHEMTRAK COMPLETES $5.0 MILLION FINANCING
FDA APPROVES FIRST HOME COLLECTION HIV TEST
CHEMTRAK ANNOUNCES JAPANESE LICENSING DEAL FOR TECHNOLOGY BREAK THROUGH IN ASTHMA PATIENT TESTING
CHEMTRAK POSTS 2ND QUARTER REVENUES OF $606,000; YEAR TO DATE REVENUES TOTAL $1.6 MILLION
ChemTrak Names FCB as Advertising Agency of Record and Reports 3rd Quarter Revenues

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters